

31 August 2023

Vanessa Nevjestic
Senior Adviser, Listings Compliance
ASX Compliance Pty Ltd
152-158 St George's Terrace
Perth WA 6000

Via email: ListingsCompliancePerth@asx.com.au

Dear Vanessa

**Response to Price and Volume Query
Arovella Therapeutics Limited (ASX:ALA) (ALA or the Company)**

We refer to ASX's letter dated 30 August 2023, titled "Price and Volume - Query".

The Company responds to ASX's letter as follows.

1. *Is ALA aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?*

ALA notes that Blue Ocean Equities yesterday circulated a report which highlighted Arovella's recent progress and upcoming milestones and announced a non-deal roadshow for interested parties. Whilst there was no new information in this summary, it was presented in a new format with outreach to an extended group of investors via social media.

ALA announced on 27 June 2023 positive data for a technology under Option from the University of North Carolina and has made public its intention to seek a licence to this technology, subject to satisfactory due diligence. This due diligence process is ongoing and the negotiations remain preliminary and early stage and no formal agreement has been reached.

ALA is also in preliminary early stage negotiations to enter into an intellectual property licence agreement with a prospective licensor, Sparx Therapeutics Inc. As at the date of this letter, negotiations are incomplete, and no formal agreement has been signed between the parties. Further, there is no certainty that ongoing discussions will lead to a formal agreement being reached or signed. In the event that an agreement is signed, ALA anticipates that it will be granted rights under the agreement to a monoclonal antibody (mAb) sequence for a novel target that is expressed in a range of cancer types, that it may choose to use to develop, manufacture and commercialise novel cell therapies for the purpose of treatment of cancer in humans.

ALA is not aware of any other material information at this time. ALA will, in line with its continuous disclosure obligations, make a further announcement to the market, if and when agreements with the prospective licensors are entered into.

2. *If the answer to question 1 is "yes".*

*(a) Is ALA relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1?
Please note that the recent trading in ALA's securities would suggest to ASX that such*

information may have ceased to be confidential and therefore ALA may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.

Yes. Further to ALA's discussions with ASX, ALA considers that its negotiations with the prospective licensors are, as at the date of this letter, incomplete and preliminary, insufficiently definite to warrant disclosure, and but for ASX forming the view that the information has ceased to be confidential, constitutes information to which the disclosure exemption under Listing Rule 3.1 applies.

(b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).

Refer to ALA's responses to paragraphs 1 and 2 above.

(c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?

Not applicable.

3. If the answer to question 1 is "no", is there any other explanation that ALA may have for the recent trading in its securities?

Not applicable.

4. Please confirm that ALA is complying with the Listing Rules and, in particular, Listing Rule 3.1.

ALA confirms that it is in compliance with the Listing Rules, and in particular, Listing Rule 3.1.

5. Please confirm that ALA's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of ALA with delegated authority from the board to respond to ASX on disclosure matters.

ALA confirms that these responses have been authorised and approved in accordance with its published Continuous Disclosure Policy.

Please contact me if you require any further information.

Yours sincerely

Dr Michael Baker

Chief Executive Officer & Managing Director



30 August 2023

Reference: ODIN79104

Mr Phillip Hains and Mr Rowan Cole
Joint-Company Secretaries
Arovella Therapeutics Limited
C/- The CFO Solution
Level 3, 62 Lygon street
Carlton, Victoria 3053

By email: phillip@thecfo.com.au
rcole@thecfo.com.au

Dear Mr Hains and Mr Cole

Arovella Therapeutics Limited ('ALA'): Price and Volume - Query

ASX refers to the following:

- A. The change in the price of ALA's securities from an intraday low of A\$0.050 to an intraday high of A\$0.060 today.
- B. The significant increase in the volume of ALA's securities traded today.

Request for information

In light of this, ASX asks ALA to respond separately to each of the following questions and requests for information:

1. Is ALA aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
 - (a) Is ALA relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in ALA's securities would suggest to ASX that such information may have ceased to be confidential and therefore ALA may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that ALA may have for the recent trading in its securities?
4. Please confirm that ALA is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that ALA's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of ALA with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **4:00 PM AWST Wednesday, 30 August 2023**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, ALA's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require ALA to request a trading halt immediately.

Your response should be sent to me by e-mail at **ListingsCompliancePerth@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in ALA's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in ALA's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to ALA's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that ALA's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Questions

If you have any questions in relation to the above, please do not hesitate to contact me.

Yours sincerely

Vanessa Nevjestic
Senior Adviser, Listings Compliance